Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cedilla Therapeutics Inc. is addressing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The current prosecution involves 1 distinct examiner and a distinct art unit. This narrow focus indicates that the company is currently prioritizing a single patent application or a specific technical area. By focusing on a single art unit, the applicant can tailor their strategy to the specific nuances of that group within the Biotechnology & Pharmaceuticals sector. This concentration allows for a more efficient use of resources during the prosecution phase.
SEAMAN, D MARGARET M is the busiest examiner, with 1 pending office action. This examiner is responsible for the only active matter in the company's portfolio. With 1 pending office action total, the applicant can focus their strategy on the specific examination style of this individual. The presence of a single art unit suggests a highly targeted approach to securing intellectual property rights. Because SEAMAN, D MARGARET M is the only examiner with 1 pending office action, the company's prosecution efforts are streamlined and focused. This allows for a clear and direct response to the office action, potentially leading to a more predictable outcome.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17808868 | TEAD INHIBITORS AND USES THEREOF | SEAMAN, D MARGARET M | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17808868 | TEAD INHIBITORS AND USES THEREOF | SEAMAN, D MARGARET M | 1625 | §102§112 | Non-Final OA | — | Pending | Jun 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCedilla Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
D Margaret M Seaman has the most, with 1 of Cedilla Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
